In this episode of Coffee with Samso, we sat down with Dustin Haines, the newly appointed CEO of Echo IQ Limited (ASX: EIQ), to unpack the company’s transformative AI-based technology for cardiovascular diagnosis. While the format shifted to Zoom to accommodate Dustin’s base in the United States, the conversation was no less in-depth as we explored how Echo IQ is aiming to solve one of the most pressing challenges in cardiovascular medicine—misdiagnosis.

 

With a 50% misdiagnosis rate in conditions like heart failure, Echo IQ’s FDA-cleared AI solution could become a game-changer for structural heart disease diagnosis. This is a timely discussion as AI continues to gain traction in medical settings and investors begin to appreciate the real-world value of clinical validation and scalable software solutions.

As always, grab your coffee and dive into the conversationo.

 

Chapters:

00:00 Start

00:10 introduction

01:47 Introducing Dustin Haines

05:42 The Cardiovascular Diagnosis Issue.

08:33 The milestones for EchoIQ Limited

13:45 What stage is EchoIQ at?

15:07 What is the core medical issue that EchoIQ is solving?

18:27 What is the accepted level of error for the EcoIQ product?

21:16 What is the realistic level of Misdiagnosis for EchoIQ?

23:58 Why is your technology good?

27:13 The EchoIQ WorkFlow Enhancement

30:06 The Revenue Pathway

33:32 Where does EchoIQ sit on the table of Market Leaders?

36:39 Reimbursement is the Key Revenue Driver.

37:46 Can EchoIQ technology be adopted to other pathways?

39:35 How far can AI go?

44:51 The Benefits and Issues of AI

46:57 Why buy EchoIQ shares?

49:54 What market capitalisation could investors of EchoIQ see in the future?

52:37 Dustin Haines' last Words

54:25 Conclusion